Susceptibility of Cholangiocarcinoma Cells to Parthenolide-Induced Apoptosis

Jong-Hyun Kim, Lan Liu, Seung-Ok Lee, Yong-Tae Kim, Kyung-Ran You, and Dae-Ghon Kim

Abstract
Cholangiocarcinomas are intrahepatic bile duct carcinomas that are known to have a poor prognosis. Sesquiterpene lactone parthenolide, which is the principal active component in medicinal plants, has been used to treat tumors. Parthenolide effectively induced apoptosis in all four cholangiocarcinoma cell lines in a dose-dependent manner. However, the sarcomatous SCK cells were more sensitive to parthenolide than the other adenomatous cholangiocarcinoma cells. SCK cells, which stably express Bcl-XL, were resistant to parthenolide, which stably express Bcl-XL, were resistant to parthenolide, whereas Bcl-XL-positive Choi-CK cells transfected with the antisense Bcl-XL showed a higher parthenolide sensitivity than the vector control cells. Molecular dissection revealed that Bcl-XL inhibited the translocation of Bax to the mitochondria. This suggests that parthenolide effectively induces oxidative stress-mediated apoptosis, and that the susceptibility to parthenolide in cholangiocarcinoma cells might be modulated by Bcl-XL expression in association with Bax translocation to the mitochondria. (Cancer Res 2005; 65(14): 6312-20)

Introduction
Cholangiocarcinomas are malignant tumors that are derived from the bile duct epithelium. They are quite prevalent in some areas of Southeast Asia where liver fluke infestations are endemic. Cholangiocarcinomas account for 77% of all primary liver tumors (1). Chronic biliary tract inflammations resulting from bacterial infections, parasitic infestations, or chronic inflammatory diseases of the biliary tract (such as primary sclerosing cholangitis) are significant risk factors for the development of cholangiocarcinomas. The prognosis for cholangiocarcinoma patients is quite poor due to the lack of an early diagnosis and the fact that the tumor is relatively resistant to chemotherapy (2–4). At the time of diagnosis, ~70% of cholangiocarcinoma patients have an occult metastasis or advanced local disease, which precludes a curative resection. Even the 30% of patients who are candidates for a curative resection develop recurrent disease at either the anastomotic site or within the intrahepatic biliary tree, and succumb due to the progression of the disease or cholangitis (5). Generally, chemotherapeutic drugs exert their antitumor effects by inducing apoptosis in cancer cells. Therefore, in order to improve the therapeutic modalities and to develop alternative treatments, new agents that induce apoptosis need to be identified and their mechanism(s) of action need to be investigated. Recently, four cholangiocarcinoma cell lines were isolated and cyogenetically characterized (6). The molecular characteristics of the four cholangiocarcinoma cell lines were further investigated and their chemosensitivities were examined.

Sesquiterpene lactones have been widely used in indigenous medical practice, including the treatment of migraines (7, 8), inflammation (9, 10), and tumors (11, 12). Parthenolide, which is the major sesquiterpene lactone found in medicinal plants such as feverfew (Tanacetum parthenium), is known to inhibit interleukin-1 tumor necrosis factor-α-mediated nuclear factor-κB activation, which is responsible for its antiinflammatory activity (13, 14). Because of their low potencies, there have been few studies on the cytotoxic and antitumor effects of the sesquiterpene lactones. However, it was recently reported that parthenolide inhibits the in vitro growth of tumor cells in a cyotoxic manner and might represent a new class of cancer chemotherapeutic drugs (15). Previously, it was reported that parthenolide has effective anticancer effects including the induction of apoptosis and growth arrest in sarcomatous hepatocellular carcinoma cells, and that oxidative stress might contribute to the parthenolide-induced apoptosis in a glutathione-sensitive manner (15). Therefore, the aim of this study was to determine if parthenolide effectively induces apoptosis and whether this apoptogenic effect is modulated by the biological characteristics or by genetic alterations in the cholangiocarcinoma cells. Interestingly, the susceptibility to parthenolide was observed in all the cholangiocarcinoma cell lines. Moreover, it was higher in the Bcl-XL-defective cholangiocarcinoma cells than in the Bcl-XL-positive cholangiocarcinoma cells. This suggests that parthenolide-mediated oxidative stress and the concomitant involvement of the Bcl-2 family molecules might play a major role in the apoptotic effect.
supplemented with 10% fetal bovine serum in air containing 5% CO₂. The lung cancer (A549 and NCIH522), colon cancer (HCT116 and HT29), breast cancer (MCF-7 and MDA-MB-213), melanoma (SK-MEK-5 and SK-MEL-2), cervical cancer (HeLa and Ca-Ski), gastric cancer (AGS and KATOIII), renal cancer (ACHN and A498), and leukemia cells (MOLT4 and HL60) were obtained from the American Type Culture Collection (Manassas, VA) and cultured under the same conditions. These cancer cell lines were treated with the indicated parthenolide concentrations for 72 hours and harvested to determine the extent of apoptotic cell death. Transfection of the Bcl-XL gene into the SCK cells was done using an expression plasmid vector encoding either human Bcl-XL cDNA (a kind gift from Prof. Yuan J; ref. 16) or the control pcDNA3 (Invitrogen, Carlsbad, CA). The transfections were carried out using lipofectin (Invitrogen) according to the manufacturer’s protocol. The sequence-verified Bcl-XL-transfected and neo-transfected cells were selected in the presence of 600 μg/mL G418 for 2 to 3 weeks. Finally, individual colonies were isolated using cloning rings, expanded and assayed for the expression of the transfected gene using Western blot analysis. For the transient or stable transfection with the antisense Bcl-XL, the Choi-CK cells were transfected with either pEGFP-3C-Bcl-XL (AS) containing the open reading frame of Bcl-XL in the EcoRI site in the antisense orientation, or the control vector pEGFP-C3 (Clontech, Palo Alto, CA). The apoptotic cells were quantified by gating the sub-G1 fraction of the green fluorescence protein (GFP)–positive cells in the DNA histogram using the LYSIS II program. The percentage of viable cells was determined by trypsin blue dye exclusion and the proportion of apoptotic cells were evaluated by Hoechst 33258 staining (1 μg/mL), which is a DNA-binding dye. At least 400 cells were counted at each time point and all the counting was carried out in a blinded manner. Detection of DNA fragmentation. The cholangiocarcinoma cells (1 × 10⁶) were seeded in 6 cm Petri dishes and allowed to attach. The cells were treated with the indicated parthenolide concentrations for 72 hours. In order to analyze the genomic DNA, the cells were harvested and collected together with the nonattached cells in the supernatant. The cells were resuspended in 0.5 mL of a lysis buffer [50 mmol/L Tris-HCl, 100 mmol/L EDTA, 0.5% SDS (pH 8.0)] containing 0.1 mg/mL RNase A. The DNA was extracted and separated on 1.5% agarose gels and electrophoresed in the presence of 0.5 μg/mL ethidium bromide, as described previously (15). Flow cytometric analysis. The cholangiocarcinoma and the other cancer cells (1 × 10⁶) were collected at set time intervals for flow cytometry using a FACScan or FACSCalibur (Becton Dickinson, San Jose, CA) with an argon laser at a wavelength of 488 nm. The trypsinized monolayer cells and the detached cells were collected at set intervals after the parthenolide treatment. Parental cholangiocarcinoma (40 μg/mL parthenolide) and 10⁶ cells suspended in 800 μL PBS together with 100 μL RNase A (1 μg/mL), and the mixture was incubated at 37°C for 30 minutes prior to the flow cytometric analysis of 2 × 10⁶ cells, as described elsewhere (17). The cell cycle was analyzed using ModFit LT 3.0 software program (Verity Software House, Topsham, ME). The sub-G₁ fraction was estimated by gating the hypodiploid cells in the DNA histogram using the LYSIS II program. Fas and FasL mRNA expression. In order to prepare the single-stranded cDNA, the mRNA was reverse-transcribed with the oligo d(T)15 primers (Amersham Pharmacia Biotech, Piscataway, NJ), which was followed by PCR amplification of the Fas mRNA or FasL mRNA. Amplification was carried out for 30 cycles in a thermal cycler (Applied Biosystems, Foster City, CA), for β-actin as an internal control and Fas. Each cycle consisted of 1 minute of denaturation at 94°C, 1 minute of annealing at 57°C, and 1 minute of extension at 72°C. The sequences used were as follows: Fas (forward, 5'-CGGAGATTGCTAAACAC-3'; reverse, 5'-TTGGATCTTTGTCGGCGT-3'; ref. 18) and β-actin (forward, 5'-CGTCTCAGGGACCACTAT-3'; reverse, 5'-CAGACATAGTCTATGGCGCC-3'; ref. 19). The FasL reverse transcriptase-PCR amplification was obtained for 35 cycles. The FasL primer sequences are as follows: forward, 5'-CAAGTCCAACATCAGGTCAT-3' (nucleotides 641-661); reverse, 5'-AACGATCTTGAAGTCTCTCTTG-3' (nucleotides 681-710; ref. 20). The PCR conditions consisted of 1 minute of denaturation at 94°C, 1 minute of annealing at 55°C, and 1 minute of extension at 72°C. The PCR products were analyzed by electrophoresis on 1.2% agarose gels. Cell lysis and immunoblotting. The cells were lysed and the nuclei were collected by centrifugation through a 30% sucrose solution (800 × g, 10 minutes at 4°C), the mitochondria were collected at 10,000 × g for 20 minutes at 4°C, and the remaining cell membranes were removed by centrifugation at 100,000 × g for 45 minutes at 4°C, as described elsewhere (17). The mouse monoclonal antibodies against p53 (DO-1) and Bcl-XL (H-3), rabbit polyclonal antibody against Bax (G-23), Bad (K-17), Bax (N-20), and Hsp60 (H-1), and goat polyclonal antibody against Bid (C-20) and actin (C-11), were acquired from Santa Cruz (Santa Cruz, CA). The mouse monoclonal antibody against Bel-2 (Ab-1) was obtained from Calbiochem (San Diego, CA). The mouse monoclonal antibodies against poly(ADP-ribose)/polymerase (C2-10) and against cytochrome c (6H2.B4) were purchased from BD-PharMingen (San Diego, CA). Measurement of the reactive oxygen species and mitochondrial transmembrane potential (ΔΨm). The intracellular generation of reactive oxygen species (ROS) was measured using the oxidation-sensitive fluorescein 5,6-carboxy-2',7'-dichlorofluorescein diacetate (Molecular Probes, Eugene, OR) as described elsewhere (21). The fluorescence of 2',7'-dichlorofluorescein, which is the highly oxidized form of 5,6-carboxy-2',7'-dichlorofluorescein, was measured using laser scanning confocal microscopy (Zeiss LSM510). In order to measure the ΔΨm, the cells were treated with 10 μM parthenolide for the indicated time, 5',6',6'-Tetraethylbenzimidoazocarboxyanine iodide (5 μg/mL, JC-1; Molecular Probes) was then added to the medium, and incubation was continued for 15 minutes in the dark. The stained cells were harvested, washed once in PBS and analyzed by flow cytometry, as described elsewhere (15). At a relatively high ΔΨm, the dye JC-1 forms J-aggregates, which emit at 590 nm (FL-2 channel). However, in the absence of or at a low ΔΨm, JC-1 exists as a monomer, remaining in the cell but emitting at 527 nm (FL-1 channel). Immunofluorescence. The cells were grown on glass coverslips, fixed with 4% parafomaldehyde, permeabilized in PBS containing 0.2% Triton X-100, and blocked with 1% bovine serum albumin. The transient transfection of Bax in fusion with the GFP gene into the SCK cells was done using lipofectin (Invitrogen) according to the manufacturer’s protocol. The cells were incubated overnight with a rabbit polyclonal antibody to Bax (N-20) at 4°C, washed, and incubated with tetramethylrhodamine isothiocyanate isomer R–conjugated swine anti-rabbit immunoglobulin. After the final wash, the cells were stained with 1 μg/mL Hoechst 33258 for 15 minutes to visualize the nuclei, and mounted with 50% glycerol in PBS at 4°C. The cells were examined using laser scanning microscopy (LCM 510, Carl Zeiss, Jena, Germany). Quantification. The densitometric data was analyzed using a Personal Densitometer SI (Molecular Dynamics, Sunnyvale, CA). The expression levels of each gene relative to the vehicle-treated control were calculated by normalizing the results against the level of glyceraldehyde-3-phosphate dehydrogenase mRNAs or actin protein, and calculating the ratio of the mRNAs from the treated cells for the indicated time intervals with the untreated controls. Statistical analysis. The data is presented as a mean ± SE of at least three independent experiments done in duplicate. Representative blots are shown. All the data was entered into the Microsoft Excel 5.0, and GraphPad Software was used to perform the two-tailed t tests or the analysis of the variance, where appropriate. P values < 0.05 were considered significant. Results Detection and quantification of parthenolide-induced apoptosis. The survival of the cholangiocarcinoma cells following treatment with various parthenolide concentrations was measured. Parthenolide effectively triggered cell death in a dose-dependent manner within 72 hours (Fig. 1A). Treatment with 10 μM/L parthenolide for 72 hours induced cell death in 49.5 ± 2.9% (mean ± SE) of the SCK cells, 35.2 ± 3.8% of the JCK cells, 30.3 ± 2.4% of the Cho-CK cells, and 35.5% ± 3.3% of the Choi-CK cells. Apoptotic cell death of the SCK cells was significantly more pronounced than that of the other cell lines (P < 0.05). Therefore, this parthenolide concentration was used in the subsequent experiments. The cells treated with 10 μM/L parthenolide were stained with Hoechst.
33258 (1 μg/mL) to measure the level of apoptotic cell death, which was revealed by the condensed chromatin and fragmented nuclear morphologies in all four cell lines (Fig. 1B). The cells displayed disintegrated nuclei and nonrandom DNA fragmentation, as assessed by agarose gel electrophoresis of the genomic DNA (Fig. 1C). The SCK cells showed a higher proportion of apoptotic internucleosomal DNA fragmentation than the other cell lines. In addition, the apoptotic cell death was further confirmed using flow cytometric analysis. Parthenolide effectively induced a substantial apoptotic sub-G1 fraction in all the cholangiocarcinoma cell lines compared with the vehicle (Fig. 1D). Furthermore, the apoptotic fraction of the SCK cells was significantly higher in the SCK cells than in the other cell lines (49.5% versus 35.2%, 30.3%, or 35.5%; P < 0.01). These results are consistent with the increased apoptosis of SCK cells.

In order to determine the effect of the parthenolide on other human cancer cell lines indicated, they were treated with 0, 1, 5, or 10 μmol/L parthenolide for 72 hours. Parthenolide effectively induced apoptosis in the various human cancer cell lines in a range of 22.7% to 62% 72 hours after treatment. In particular, melanoma cells, SK-MEK-5, and SK-MEL-2 showed a higher susceptibility to parthenolide-induced apoptosis than the other cancer cells, i.e., the proportion of apoptotic cells were 62% and 54.5%, respectively. In contrast, lung cancer cells, A549 and NCIH522 showed minimal susceptibility, i.e., 32.5% and 22.7%, respectively (Fig. 1E).

The effective concentration (10 μmol/L) of parthenolide seems to be quite high. Therefore, this study examined whether or not a low parthenolide concentration also has an antitumor effect on the cholangiocarcinoma cell lines. The results showed that a sublethal dose (2 μmol/L) of parthenolide effectively inhibited cell growth by inhibiting the cell cycle progression compared with the vehicle controls. Flow cytometric analysis revealed that parthenolide significantly enhanced G1 arrest in all four cell lines, which was accompanied by a decrease in the S phase (Table 1). These results suggest that the low parthenolide concentration can be connected to its in vivo antitumor effect.
Expression of p53 and Bcl2/Bcl-X<sub>L</sub>. In order to examine the genetic changes that might be related to the drug susceptibility, the expression of the p53 and Bcl-2/Bcl-X<sub>L</sub> proteins was examined. This study used a mouse monoclonal antibody (DO-1), which recognizes the wild-type and mutant p53 proteins of human origin. The SCK cells did not express the p53 protein. The other three ordinary cholangiocarcinoma cell lines expressed either the wild-type or the mutant p53 (Fig. 2A). The p53 gene is one of the most frequently mutated genes in all types of cancer (22), with most mutations occurring in exons 5 to 8 (23). Mutations occurring in those regions are usually missense mutations that alter the DNA binding site conformation. Single-strand conformation polymorphism analysis of the genetic changes revealed that the Choi-CK cells did not have any shifted bands in the p53 gene in exons 5 to 8. In contrast, abnormal band shifts were detected in exon 6 of the JCK cells and exon 8 of the Cho-CK cells, suggesting a dysfunction in the p53 gene in the JCK and Cho-CK cells but a wild-type p53 function in the Choi-CK cells (data not shown).

Bcl-2 protects the cells against apoptosis, and the inhibition of Bcl-2 expression promotes apoptosis in response to a variety of stimuli (24, 25). Therefore, the Bcl-2 protein expression level was determined in the cholangiocarcinoma cell lines. All the cholangiocarcinoma cell lines exhibited Bcl-2 expression. However, the expression of Bcl-X<sub>L</sub>, which is another Bcl-2-related anti-apoptotic protein, was negative in the SCK cells, whereas it was positive in the other three adenomatous cholangiocarcinoma cells (Fig. 2B). Human hepatoma cells, SK-HEP-1 and Hep 3B cells were used as the positive and negative controls of Bcl-2 expression, respectively (17).

Modulation of p53, Fas/FasL, and Bcl2/Bcl-X<sub>L</sub> expression by parthenolide. Western blot analysis was done after treating the cholangiocarcinoma cell lines with 10 μmol/L parthenolide for 72 hours. Parthenolide significantly increased the p53 protein expression level in the adenomatous cholangiocarcinoma cells irrespective of the p53 function (Fig. 3A).

The expression of Fas/FasL in cholangiocarcinoma cells was then examined because Fas/FasL mediates various types of drug-induced apoptosis (26). Parthenolide decreased the Fas mRNA expression level in all the cholangiocarcinoma cell lines. Parthenolide also decreased the Fasl mRNA expression level in the three adenomatous cholangiocarcinoma cell lines but not in the sarcomatous SCK cells (Fig. 3B). These observations are consistent with a report showing that parthenolide suppresses the Fasl/FasL expression at the mRNA level in T cells (27). However, parthenolide did not inhibit Fasl expression in the susceptible SCK cells. Although the mechanism of this different regulation of Fasl is unclear, the drug-induced Fasl transcription and apoptosis was reported to be inhibited by Bcl-X<sub>L</sub> (28). Therefore, Fasl expression may not be inhibited by parthenolide in the Bcl-X<sub>L</sub>-defective SCK cells. This study used human hepatoma cells, SK-HEP-1 and Hep 3B cells, as positive and negative controls, respectively. The SK-HEP-1 cells expressed Fas mRNA and the Hep 3B cells did not express Fas mRNA, as described elsewhere (17).

In order to examine the potential role of the Bcl-2 family members in the parthenolide-induced apoptosis, this study examined the effects of parthenolide on the expression or cleavage of several members of this family. Parthenolide did not alter the expression of the antiapoptotic Bcl-2 or Bcl-X<sub>L</sub> in the adenomatous cholangiocarcinoma cell lines after being treated with 10 and even

<table>
<thead>
<tr>
<th>Table 1. Cell cycle phase distribution in the cholangiocarcinoma cells following treatment with a sublethal dose of parthenolide</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

NOTE: Cell cycle phase distribution was determined by flow cytometric analysis following treatment with 2 μmol/L parthenolide for 72 hours. The values are means ± SE.

*P < 0.01.

<sup>1</sup>P < 0.05.
20 μmol/L parthenolide for 72 hours (Fig. 3C). However, considering that the SCK cells exhibited defective Bcl-XL expression and altered FasL regulation, the defective Bcl-XL expression might have contributed to the susceptibility to parthenolide-mediated apoptosis. This is because the parthenolide-mediated anticancer effects may be related to oxidative stress, as described in the literature (15). Accordingly, the involvement of the proapoptotic Bcl-2 family, such as Bid, Bad, Bak, and Bax, was examined. In contrast to there being no alterations in Bad expression, cleavages of Bid by parthenolide were shown in the four cholangiocarcinoma cell lines. Parthenolide concomitantly induced Bak and Bax expressions in all four cell lines, even though the Cho-CK cells might express the high molecular weight oligomer or complex of Bax, which is consistent with a previous report (29). The caspase-8 cleavage of Bid generates tBid, which is inserted into the mitochondrial outer membrane. The mitochondrial tBid subsequently recruits Bax into the outer membrane bilayer and induces the intramembrane oligomerization of Bax (30) and Bak (31), causing these proapoptotic Bcl-2 members to form the proposed conduit for the release of cytochrome c from the organelles (32).

Ectopic overexpression of Bcl-XL leads to resistance to parthenolide-mediated apoptosis. Two stable cell lines that overexpress Bcl-XL from the Bcl-XL defective SCK cells, termed XL-21 and XL-26, were established in order to determine if Bcl-XL expression contributes to resistance against parthenolide-induced apoptosis. The vehicle did not alter the level of apoptotic cell death in both the vector control cells and Bcl-XL transfectants. In contrast, Bcl-XL expression significantly inhibited the parthenolide-induced apoptosis the stable transfectants to ~50% of the level of the control cells in (29.2 ± 3.8% versus 74.5 ± 4.2% and 64.5 ± 6.6%; P < 0.01; Fig. 4A). Therefore, Bcl-XL expression reduced the sensitivity to drug-induced apoptosis, which might be mediated by the inhibition of oxidative damage. In order to test this hypothesis, another apoptosis inducing agent, 4-(N-hydroxyphenyl)retinamide (4HPR), was used because this drug has also been reported to induce oxidative injury in cancer cells (33). Bcl-XL expression also effectively inhibited the 4HPR-induced apoptosis to ~40% of the control cells (37.2 ± 4.8% and 35.5 ± 5.4% versus 94.2 ± 6.5% and 84.4 ± 7.5%; P < 0.01) in the stable transfectants (Fig. 4B).

Two stable cell lines (AS1 and AS2) transfected with an antisense expression plasmid of Bcl-XL in fusion with a GFP were established

Figure 3. Modulation of p53, Fas/FasL, and Bcl-2 family expression by parthenolide. A, immunoblotting of p53 in the cholangiocarcinoma cells cultured in the presence (+) of 10 μmol/L parthenolide (P) or vehicle (−; V) for 72 hours. Thirty micrograms of the extracted proteins were resolved by 12% SDS-PAGE and transferred to the membrane. The blots were probed with a monoclonal antibody to p53 (DO-1) and then stripped and reprobed with a monoclonal antibody to actin as the loading control. The experiments were done at least thrice and the result of one representative experiment is shown. Columns, means; bars, ± SE. *, P < 0.05; **, P < 0.01. B, Fas/FasL mRNA expression was analyzed by reverse transcriptase-PCR using the primers for Fas/FasL in the cholangiocarcinoma cells cultured in the presence (+) of 10 μmol/L parthenolide (P) or vehicle (−; V) for 72 hours. The experiments were done at least thrice and the result of one representative experiment is shown. Columns, means; bars, ± SE. *, P < 0.05; **, P < 0.01. C, immunoblotting of Bcl-2, Bcl-XL, Bad, Bid, Bak, and Bax in the cholangiocarcinoma cells cultured in increasing concentrations, 0 μmol/L (first lane), 10 μmol/L (second lane), and 20 μmol/L (third lane), of parthenolide (P) for 72 hours. Thirty micrograms of the extracted proteins were resolved by 12% SDS-PAGE and transferred to the membrane. The blots were probed with a monoclonal or polyclonal antibody against Bcl-2 (Ab-1), Bcl-XL (H-5), Bad (K-17), Bid (C-20), Bak (G-23), and Bax (N-20), and then stripped and reprobed with the monoclonal antibody to actin as a loading control. The experiments were done at least thrice and the result of one representative experiment is shown.
to determine if the prevention of Bcl-XL expression might lead to the enhanced susceptibility to parthenolide in Bcl-XL-positive Choi-CK cells. The Bcl-XL expression was effectively inhibited by >65% in those transfecants. The AS1 and AS2 cells were more susceptible to parthenolide, i.e., ∼33.5% and 35.5% of the transfecants were apoptotic (P < 0.01), compared with 7.2% and 8.5% of the empty vector control cells (VC-1 and VC-2; Fig. 4C). Similarly, the transient transfection experiments showed that the Choi-CK cells transfected with the antisense Bcl-XL cDNA were more susceptible to parthenolide, i.e., ∼71.9% of the transfecants were apoptotic (P < 0.01), compared with 40.3% of the empty vector control cells (data not shown). These results suggest that the inhibition of Bcl-XL expression correlates positively with the apoptotic cell death in Choi-CK cells.

**Bcl-XL overexpression inhibits mitochondrial translocation of Bax and the generation of reactive oxygen species.** Because Bid activation and Bak and Bax overexpression did not seem to differentiate the drug susceptibility according to the Bcl-XL expression level, this study determined if Bcl-XL expression regulates the mitochondrial translocation of Bax between the Bcl-XL-positive (XL-21 and XL-26) and Bcl-XL-negative (VC-1 and VC-2). Following a death signal, Bax translocates from the cytosol to the mitochondria at which time the Bax conformation changes (34). This mitochondrial localization and its oligomerization play an important role in triggering apoptosis (35). Bak, which is another proapoptotic molecule, normally resides in the mitochondria and undergoes a rearrangement to form the homomeric complexes following Bax insertion into the mitochondria. Despite this functional cooperation between Bax and Bak, Bax is essential for mitochondrial permeabilization (36). Therefore, the Bax expression level was measured in the cytosol and in the mitochondrial extracts after drug treatment for 48 hours (Fig. 5A). Parthenolide effectively decreased the cytosolic Bax level in the vector control cells (VC-1 and VC-2), whereas it had little effect on the Bcl-XL transfectants (XL-21 and XL-26). Accordingly, the accumulation of Bax increased proportionally in the mitochondria of the vector control cells. In order to further confirm the inhibition of Bax translocation by Bcl-XL, the SCK cells were transiently cotransfected with the GFP-Bax fusion vector and a mitochondria targeting vector pDsRed1-Mito (Clontech), and then treated with parthenolide (Fig. 5B). Bax was localized in the cell cytoplasm and nucleus. Parthenolide effectively translocated the Bax to the perinuclear area, which overlaps with the localization of the mitochondria targeting the fluorescence. In contrast, parthenolide barely translocated Bax to the mitochondria in the SCK cells transfected with Bcl-XL, which is localized at the mitochondria. This suggests that Bcl-XL effectively inhibited the parthenolide-induced translocation of cytosolic Bax to the mitochondria. Previously, it was reported that parthenolide induced oxidative damage in hepatoma cells in a glutathione-sensitive manner and that this oxidative damage led to ROS generation, \( \Delta \Psi_m \) reduction, cytochrome c release, caspase activation, and finally apoptotic cell

---

**Figure 4.** Effect of Bcl-XL expression on apoptotic cell death in SCK cells. A, protein expression of Bcl-XL in the stably transfected SCK cells (XL-21 and XL-26) compared with the vector control cells (VC-1 and VC-2). Immunodetection of Bcl-XL was done using the mouse anti-Bcl-XL monoclonal antibody (H-5). The blots were then stripped and reprobed with the monoclonal antibody to actin as a loading control (top). Quantification of the apoptotic fraction was done by flow cytometric analysis. The cells were grown for 72 hours in the presence of either the vehicle or 10 \( \mu \)mol/L parthenolide. The sub-G1 fraction was estimated by gating the hypodiploid cells in the histogram using the LYSIS II program. The DNA contents are plotted on the linear abscissa \((M_1, \text{ apoptotic fraction})\). Points, mean; bars, \( \pm \) SE; *, P < 0.01 compared with the vector controls. B, protein expression of Bcl-XL in the stably transfected SCK cells (XL-21 and XL-26) compared with the vector control cells. In order to further confirm the inhibition of Bcl-XL expression plasmid of Bcl-XL in fusion with a GFP compared with the vector control cells (VC-4 and VC-5; left). The stable transfectants were then treated with either 10 \( \mu \)mol/L parthenolide or the vehicle for 36 hours. The cells were harvested and stained with propidium iodide. Quantification of the apoptotic fraction was done by flow cytometric analysis (right); *, P < 0.01 compared with the vector controls.

---

**Figure 5.** Effect of Bcl-XL expression on apoptotic cell death in SCK cells. A, protein expression of Bcl-XL in the stably transfected SCK cells (XL-21 and XL-26) compared with the vector control cells (VC-1 and VC-2). Immunodetection of Bcl-XL was done using the mouse anti-Bcl-XL monoclonal antibody (H-5). The blots were then stripped and reprobed with the monoclonal antibody to actin as a loading control (top). Quantification of the apoptotic fraction was done by flow cytometric analysis. The cells were grown for 72 hours in the presence of either the vehicle or 10 \( \mu \)mol/L parthenolide. The sub-G1 fraction was estimated by gating the hypodiploid cells in the histogram using the LYSIS II program. The DNA contents are plotted on the linear abscissa \((M_1, \text{ apoptotic fraction})\). Points, mean; bars, \( \pm \) SE; *, P < 0.01 compared with the vector controls. B, protein expression of Bcl-XL in the stably transfected SCK cells (XL-21 and XL-26) compared with the vector control cells. In order to further confirm the inhibition of Bcl-XL expression plasmid of Bcl-XL in fusion with a GFP compared with the vector control cells (VC-4 and VC-5; left). The stable transfectants were then treated with either 10 \( \mu \)mol/L parthenolide or the vehicle for 36 hours. The cells were harvested and stained with propidium iodide. Quantification of the apoptotic fraction was done by flow cytometric analysis (right); *, P < 0.01 compared with the vector controls.
Bcl-XL overexpression inhibits ∆Ψ\textsubscript{m} reduction, cytochrome c release, and poly(ADP-ribose) polymerase cleavage. ROS generation was increased in the vector control cells in a time-dependent manner. The maximum 2,7'-dichlorofluorescein fluorescence intensity was reached within 24 hours of the parthenolide treatment (Fig. 5C). The ectopic expression of Bcl-XL effectively decreased the production of ROS to 40% of the level in the control cells. H\textsubscript{2}O\textsubscript{2} was used as a positive control.

**Discussion**

DNA ladder, Hoechst staining, and flow cytometric analysis was used to confirm the parthenolide-induced apoptosis in cholangiocarcinoma cells as well as in other various cancer cells examined in this study. In particular, parthenolide-mediated apoptotic cell death was observed in all four cell lines (designated as SCK, JCK, Cho-CK and Choi-CK cells), but the SCK cells were more susceptible (Fig. 1A) whereas a sublethal dose of parthenolide (2 μmol/L) inhibited tumor cell growth via G1 arrest in all four cell lines. In order to discriminate the genetic heterogeneity involved in the different parthenolide susceptibility, the basal expression of p53 and Bcl-2/Bcl-X\textsubscript{L} was compared. The more susceptible SCK cells showed defective p53 and Bcl-XL expression, compared with the other adenomatous cholangiocarcinoma cells.

**Figure 5.** Reduction of ROS generation by ectopic overexpression of Bcl-XL in SCK cells. A, the cells were treated with 10 μmol/L parthenolide (P) for 48 hours. Thirty micrograms of cytosolic (c) and mitochondrial (m) proteins were separated by 15% SDS-PAGE. Immunodetection of Bax was done using specific antibodies, as detailed in Materials and Methods, and was visualized by enhanced chemiluminescence. The actin and Hsp60 antibodies were used as the cytoplasmic and mitochondrial markers, respectively. The experiments were done at least thrice and the result of one representative experiment is shown. B, the cells cotransfected with the GFP-Bax fusion vector and a mitochondrial targeting pDsRed-Mito (top) or with the GFP-Bcl-X\textsubscript{L} fusion vector and the mitochondrial targeting pDsRed-Mito (middle), or transfected with the GFP-Bcl-X\textsubscript{L} fusion vector only (bottom) were for 1 μg/mL Hoechst 33258 staining in order to visualize the nuclei (blue) and for indirect immunofluorescence staining for Bax (red). The experiments were done at least thrice and the result of one representative experiment is shown. Bar, 20 μm. C, following treatment with 10 μmol/L parthenolide, 2,7'-dichlorofluorescein fluorescence was measured using confocal microscopy at the indicated time intervals in the control cells transfected with the empty vector. 2,7'-Dichlorofluorescein fluorescence of the SCK cells stably expressing Bcl-XL was compared with that of the control cells after treating them with 10 μmol/L parthenolide for 24 hours. The relative 2,7'-dichlorofluorescein (DCF) fluorescence intensity per cell was calculated as described in Materials and Methods (right). Columns, means; bars, ± SE. **, P < 0.01 compared with the vector control treated with parthenolide for 12 hours. The experiments were done at least thrice and the result of one representative experiment is shown.
The parthenolide induced mutant p53 overexpression in the JCK and Cho-CK cells, and the wild-type p53 overexpression in the Choi-CK cells (Fig. 3A). Therefore, parthenolide effectively triggered apoptotic cell death in the various types of cholangiocarcinoma cells, irrespective of whether they expressed the wild-type or mutant p53 gene. Chemotherapeutic drugs, such as doxorubicin, methotrexate, or bleomycin, up-regulate the membrane Fas and Fasl expression level, which is followed by the induction of Fas-dependent apoptosis (38–40). In this study, all four cholangiocarcinoma cell lines showed the heterogeneous expression of Fas/Fasl mRNA. Parthenolide decreased Fas/Fasl mRNA expression level in all the cholangiocarcinoma cells with the exception of the SCK cells where the Fasl mRNA expression level increased. Furthermore, parthenolide also triggered apoptosis in the hepatoma cell lines, including Hep 3B and PLC/PRF cells, which are known to exhibit defective Fas expression (17). Therefore, parthenolide-induced apoptosis seems to be independent of Fas/Fasl expression.

Parthenolide effectively induced Bax translocation to the mitochondria in the vector control cells and this translocation was minimal in the Bcl-XL-expressing SCK cells. Even though the mechanisms responsible for Bax insertion into the mitochondrial membrane and the localization of Bax within the mitochondria are unclear, Bid, a BH3-only Bax-interacting protein, is known to trigger Bax integration in the outer mitochondrial membrane. Bid can induce a change in the Bax conformation leading to the exposure of its NH$_2$-terminal domain (29). The NH$_2$-terminal domain of Bax exerts repressing activity on the targeting of Bax to the mitochondrial membranes, possibly by interfering with the hydrophobic COOH-terminal membrane-anchoring domain (41). Bax dimerization seems to be another critical event for Bax integration in the membrane (42). Both Bcl-2 and Bcl-XL could prevent Bax oligomerization and insertion by binding directly to Bax. Therefore, Bcl-XL effectively prevents the Bax translocation to the mitochondria and subsequently reduces the mitochondrial membrane potential and cytochrome c release. The mechanism(s) by which Bax triggers the release of cytochrome c from the mitochondria following its membrane insertion is still unclear. However, Bax may stimulate the opening of the permeability transition pore through an interaction with the adenine nucleotide translocator (43), which may lead to channel formation (29).

Sesquiterpene lactones have an α-methylene γ-lactone functionality as an electrophilic agent and are prone to reactions with biological nucleophiles such as the sulphhydril groups of the reduced glutathione, proteins, and parts of the DNA (44). Therefore, the decrease in the cellular glutathione levels both in vitro and in vivo has been observed in tumor cells exposed to sesquiterpene lactones (45). A previous study consistently showed that parthenolide-mediated oxidative stress resulted mainly from reduced glutathione depletion and ROS generation, and that the tumor cell sensitivity to parthenolide seems to correlate with the glutathione metabolism (15). This study showed that Bax translocation correlates with ROS production. The results showed that the Bcl-XL-mediated inhibition of Bax translocation decreased the parthenolide-induced ROS generation upstream of oxidative stress, and subsequently inhibited the reduction in the mitochondrial membrane potential. Finally, Bcl-XL inhibited the release of cytochrome c to the cytoplasm, poly(ADP-ribose) polymerase cleavage, and apoptotic cell death. These results show that Bax translocation may be critical in parthenolide-induced apoptosis and that the modulation of Bax translocation may alter the susceptibility of the cholangiocarcinoma cells to parthenolide-induced apoptosis.

In summary, parthenolide and its derivatives may be effective anticancer agents against cholangiocarcinoma because they can effectively induce apoptosis in cholangiocarcinoma cells. Although the molecular mechanism(s) for the parthenolide-induced cancer cell apoptosis are poorly understood, oxidative stress and the Bcl-2 family molecules might be involved. In particular, Bid activation and Bax translocation are linked to ROS production and caspase activation. The defective expression of Bcl-XL might increase the drug susceptibility as a result of the enhanced Bax translocation. Therefore, these molecular mechanisms may be applicable to a chemotherapeutic strategy for cholangiocarcinoma cells.

Acknowledgments

Received 11/23/2004; revised 3/13/2005; accepted 4/14/2005.

Grant support: The Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (A050328) and the 21C Frontier Functional Human Genome Project from Ministry of Science and Technology of Korea (FG04-1101).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Prof. Juhyung Yuan for providing the plasmids, and the Korea Basic Science Institute for the laser scanning microscopy.
References

Susceptibility of Cholangiocarcinoma Cells to Parthenolide-Induced Apoptosis

Jong-Hyun Kim, Lan Liu, Seung-Ok Lee, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/65/14/6312

Cited articles
This article cites 42 articles, 16 of which you can access for free at:
http://cancerres.aacrjournals.org/content/65/14/6312.full#ref-list-1

Citing articles
This article has been cited by 6 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/65/14/6312.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.